Drugs / Montanide ISA 720 VG
last change Jan 2015 re-read 2 minutes ago

Montanide ISA 720 VG

Developed for
melanoma tumor antigen Gp90
Investigated by
Hassane M. Zarour, MD · National Cancer Institute (NCI)

Trials 1 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00819806 Jan 2009 → May 2012 melanoma tumor antigen Gp90 Hassane M. Zarour, MD Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Montanide ISA 720 VG “PF-3512676, Montanide ISA 720 VG and MHC class I peptides from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) in three subcutaneous injections” NCT00819806
Route Subcutaneous “PF-3512676, Montanide ISA 720 VG and MHC class I peptides from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) in three subcutaneous injections” NCT00819806